Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Early Stage Triple-Negative Breast Carcinoma: full-pipeline trial registry
5 of 6 indexed Early Stage Triple-Negative Breast Carcinoma trials are currently recruiting.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 5 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Early Stage Triple-Negative Breast Carcinoma: 6 US clinical trials tracked, 5 recruiting.
Early Stage Triple-Negative Breast Carcinoma is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Alliance for Clinical Trials in Oncology, running 1 of these trials.
Enrollment posture brief
Registry condition early-stage-triple-negative-breast-carcinoma
OPEN 5 | RECR 83% | LATE 2 | EARLY 2 | RANK #2866 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Alcoholic Hepatitis (83% recruiting · 6 trials)
Early Stage Triple-Negative Breast Carcinoma lists 5 open slots (83% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Early Stage Triple-Negative Breast Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Early Stage Triple-Negative Breast Carcinoma is recruiting above its size-band peers.
5 of 6 indexed trials (83.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Early Stage Triple-Negative Breast Carcinoma research.
Alliance for Clinical Trials in Oncology accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.
-
Typical Early Stage Triple-Negative Breast Carcinoma enrolment sits around 324 participants.
Median target enrolment is 324 among the 6 trials that report a genuine target (sentinel values excluded). 2 of those (33.3%) plan for fewer than 100 participants.
-
Early Stage Triple-Negative Breast Carcinoma research is mostly interventional.
5 interventional and 1 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
SWOG Cancer Research Network
NCT05929768
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Alliance for Clinical Trials in Oncology
NCT05812807
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
Mayo Clinic
NCT06349642
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
Cedars-Sinai Medical Center
NCT07017673
TNBC Gut Microbiota During Neoadjuvant Treatment
Scripps Health
NCT06610097
Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
M.D. Anderson Cancer Center
NCT07407920
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Early Stage Triple-Negative Breast Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Early Stage Triple-Negative Breast Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Early Stage Triple-Negative Breast Carcinoma page
6 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Early Stage Triple-Negative Breast Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Alliance for Clinical Trials in Oncology sponsors the most Early Stage Triple-Negative Breast Carcinoma trials on record, review their full trial history before evaluating a specific study. See Alliance for Clinical Trials in Oncology's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Early Stage Triple-Negative Breast Carcinoma condition card totals 6 registered trials; most-linked intervention Biospecimen Collection; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.